The Safety and Arterial Occlusive Events Profiles Observed With Response-based Ponatinib Dosing Regimens

Pharmacy Times^® interviewed Hagop Kantarjian, MD, the professor and chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, on one of his presentations at the 62nd ASH Annual Meeting and Exposition. The presentation looks at the efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia who failed one or more second-generation tyrosine kinase inhibitors.

In this video, Kantarjian discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.